setup still look bit challeng
mostli in-lin cc sale growth ep ahead
sale street/bofaml estimate constant
currenc growth in-lin fx vs estimate gm opm
slightli ahead mix fx lead adj ep vs street incl benefit
lower share count first look overview result
bounce-back pharma/apac still soft
two main pain-sourc link delay purchas india mass spec
weak esp high-end ms biomed accentu sale forc
realign us sequenti improv still histor level
overal sale pharma custom apac growth cc
driven china india sale flat view issu appear
wat-specif support long-term bearish view name
outlook impli ramp still steep buyback help
despit sequenti improv continu view fy outlook challeng
given increment tougher comp organ vs need
organ growth achiev organ fy midpoint
guid addit management lower fy adj ep outlook fx although
share buy-back author allow offset
bought share
lower sale target larg diminish
fx tailwind lower adj ep est accordingli although
share buyback could provid upsid reiter under-perform rate po
see continu see organ growth cap near-term given headwind
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
corp lead supplier
analyt instrument consum
product use mainli research
qualiti assur applic pharmaceut
life scienc biochem industri academ
govern custom compani
posit liquid chromatographi market
busi posit
mass spectrometri market
posit thermal analysi market
water face difficult market condit
product cycl share shift market
expect continu soft perform
view target ambiti believ
dynam take time play
share buyback may off-set earn
soft expect slower organ growth
lead under-perform rel peer
po base dcf analysi assum wacc
termin growth impli pe multipl estim
in-lin histor trade level past year believ multipl
justifi given current growth profil peer-group valuat
slow china tariff/trad war escal weaker global economi share
loss competitor slowdown pharma biotech spend downsid
risk price object upsid risk po aggress capit
deploy faster expect uptak new product acquisit
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
